




TFW 2183

PATENT
ATTORNEY DOCKET NO. 50294/016001

Certificate of Mailing: Date of Deposit: December 19, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Jeremy Waterman
Printed name of person mailing correspondence


Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Tedesco et al. Art Unit: 2183
Serial No.: 10/521,109 Examiner: Not yet assigned
Filed: January 11, 2005 Customer No.: 21559
Title: Antibodies Anti-C5 Component of the Complement System and Their Use

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. A copy of a search report from a corresponding international application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: December 16, 2005

Susan M. Michaud

Susan M. Michaud, Ph.D.

Reg. No. 42,885

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50294/016001
	Serial No.	10/521,109
	Applicant	Tedesco et al.
	Filing Date	January 11, 2005
	Group	2183
	IDS Filed	December 19, 2005

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 02/30985	4/18/02	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Evans et al., "In Vitro and In Vivo Inhibition of Complement Activity by a Single-Chain Fv Fragment Recognizing Human C5," Mol. Immunol. 32:1183-1195, 1995.					
	Fitch et al., "Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass," Circulation 100:2499-2506, 1999.					
	Thomas et al., "Inhibition of Complement Activity by Humanized Anti-C5 Antibody and Single-Chain Fv," Mol. Immunol. 33:1389-1401, 1996.					
	Wang et al., "Amelioration of Lupus-like Autoimmune Disease in NZB/W F1 Mice After Treatment with a Blocking Monoclonal Antibody Specific for Complement Component C5," Proc. Natl. Acad. Sci. U.S.A. 93:8563-8568, 1996.					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	